AZ's Lynparza misses the mark in gastric cancer trial


AstraZeneca ($AZN) has been scouting around for ways to pad its cancer sales. But it looks like a Lynparza label expansion in advanced gastric cancer isn’t going to be one of them anytime in the near future.

Wednesday, the pharma giant announced its ovarian cancer-fighter had missed its primary endpoint in a Phase III study, failing to beat out solo paclitaxel at extending overall survival when combined with the chemo med. In addition to missing the mark in the overall study population, Lynparza also came up short among patients whose tumors tested negative for the Ataxia-Telangectasia mutated protein, AZ said.

It’s a blow for Lynparza, which the company has predicted would bring in $2 billion a year in peak sales. Not only does the therapy belong to a new class of treatments--PARP inhibitors, designed to zero in on cancer cells and leave patients’ normal cells untouched--but it also belongs to a group of products AstraZeneca is counting on to help it stay the course of recently launched generics to blockbuster statin Crestor. While the British drugmaker has others chipping in growth--diabetes meds Farxiga and Onglyza, to name a couple, impressed in Q1--CEO Pascal Soriot called out Lynparza on a conference call with investors as a highlight among the company’s cancer launches.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

It’s no secret that AZ is looking at cancer in particular, too, to help it bulk up--and has been ever since it delivered a resounding no to wannabe merger partner Pfizer ($PFE) back in 2014. It’s struck several oncology deals so far--many in the red-hot immunotherapy space--and recently, rumors surfaced that it was eyeing a bid for contested target Medivation ($MDVN), whose prostate cancer phenom Xtandi has also helped it draw interest from the likes of Sanofi ($SNY), Pfizer, Novartis ($NVS) and Amgen ($AMGN).

Of course, AstraZeneca also has other Phase III programs for Lynparza in the works--and it’s hoping those will pan out differently. “We … remain confident in Lynparza’s clinical activity in a range of tumor types, including its approved use in BRCA-mutated ovarian cancer,” CMO Sean Bohen said in a statement.

- read the release

Special Report: The top 15 pharma companies by 2014 revenue - AstraZeneca

Related Articles:
AstraZeneca plots cost cuts to save $1.1B as Crestor generics loom
AZ, Pfizer, Novartis could all vie with Sanofi for Medivation: Bloomberg
AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation
AstraZeneca eyes $2B in sales with FDA nod for ovarian cancer fighter Lynparza


Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.